We are live on ! Find out more
NGNE icon

Neurogene
NGNE

22 hedge funds and large institutions have $27.6M invested in Neurogene in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

16% more funds holding

Funds holding: 19 → 22 (+3)

33% less capital invested

Capital invested by funds: $41.1M → $27.6M (-$13.4M)

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

Holders
22
Holders Change
+3
Holders Change %
+15.79%
% of All Funds
0.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
5
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RA
Royce & Associates
New York
+$639K
2
Jane Street
Jane Street
New York
+$152K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$123K
4
DCM
Driehaus Capital Management
Illinois
+$56.7K
5
U
UBS
Switzerland
+$22.4K

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$1.78M
2
Franklin Resources
Franklin Resources
California
-$779K
3
FCM
Farallon Capital Management
California
-$451K
4
BA
BlackRock Advisors
Delaware
-$82.3K
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$38.1K

NGNE Hedge Fund Activity: Q3 2014 in Review

22 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q3 2014, worth a combined $27.6M — down 33% from $41.1M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new NGNE positions and 3 closed out — a net gain of 3 holders — while 2 added to existing stakes and 5 trimmed.

The largest buyer was Royce & Associates, opening a new position worth an estimated $639K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $1.78M sold.

  • 22 institutional investors held Neurogene (NGNE) as of Q3 2014, up from 19 in Q2 2014.
  • Funds reported $27.6M of Neurogene stock for Q3 2014, down 33% quarter-over-quarter.
  • 6 funds opened new Neurogene positions in Q3 2014 and 3 closed out, a net change of +3 holders.
  • The largest Neurogene buyer in Q3 2014 was Royce & Associates, an estimated $639K added.
  • The largest Neurogene seller in Q3 2014 was Sphera Funds Management, an estimated $1.78M sold.

Based on aggregated 13F filings for Q3 2014.